Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CUL4A | Q13619 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | DNMT3B | Q9UBC3 | 4/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30886752 | 1.00 | MAPT (0.39) | MAPTKDM4EL3MBTL1MEN1GAA | |
| SCHEMBL1021883 | 0.88 | MEN1 (0.44) | MAPTKDM4EL3MBTL1MEN1GAA | |
| SCHEMBL30844063 | 0.88 | MEN1 (0.44) | MAPTKDM4EL3MBTL1MEN1GAA | |
| SCHEMBL11451379 | 0.78 | GPR35 (0.45) | MAPTKDM4EL3MBTL1MEN1GAA | |
| SCHEMBL5486010 | 0.76 | HTT (0.44) | MAPTKDM4EL3MBTL1MEN1GAA | |
| SCHEMBL1935386 | 0.74 | KDM4E (0.39) | MAPTKDM4EL3MBTL1MEN1GAA | |
| SCHEMBL10819483 | 0.74 | ALDH1A1 (0.43) | MAPTKDM4EL3MBTL1MEN1GAA | |
| SCHEMBL18555673 | 0.73 | MEN1 (0.41) | MAPTKDM4EL3MBTL1MEN1GAA | |
| SCHEMBL15017705 | 0.73 | TDP1 (0.60) | MAPTL3MBTL1MEN1KMT2AALDH1A1 | |
| SCHEMBL11743037 | 0.73 | GPR35 (0.49) | MAPTKDM4EL3MBTL1MEN1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 217 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016142952-A1 | PROCESS FOR PREPARATION OF VILAZODONE AND ITS NOVEL INTERMEDIATES | NOSCH LABS PRIVATE LIMITED (IN) | 2016-09-15 | — | — | WO | claimed |
| WO-2008013427-A1 | ORGANIC TFTS AND METHOD FOR FABRICATING THE SAME | LG CHEM, LTD. (KR) | 2008-01-31 | — | — | WO | claimed |
| WO-2025050647-A1 | IONIZABLE CATIONIC LIPID COMPOUNDS AS WELL AS PREPARATION METHOD THEREFOR AND USE THEREOF | 晟迪生物医药(苏州)有限公司 | 2025-03-13 | — | — | WO | disclosed |
| CN-117986153-A | Ionizable cationic lipid compound, and preparation method and application thereof | 晟迪生物医药(苏州)有限公司 | 2024-05-07 | — | — | CN | disclosed |
| EP-3096369-B1 | ORGANIC SOLAR CELL AND METHOD FOR MANUFACTURING SAME | LG CHEMICAL LTD (KR) | 2020-10-14 | — | — | EP | disclosed |
| US-20160343956-A1 | ORGANIC SOLAR CELL AND METHOD FOR MANUFACTURING SAME | LG CHEMICAL LTD (KR) | 2016-11-24 | — | — | US | disclosed |
| EP-3096369-A1 | ORGANIC SOLAR CELL AND METHOD FOR MANUFACTURING SAME | LG Chem, Ltd. (KR) | 2016-11-23 | — | — | EP | disclosed |
| EP-1373204-B1 | HETEROCYCLIC COMPOUNDS | JANSSEN PHARMACEUTICALS INC (US) | 2016-10-26 | — | — | EP | disclosed |
| WO-2016142952-A1 | PROCESS FOR PREPARATION OF VILAZODONE AND ITS NOVEL INTERMEDIATES | NOSCH LABS PRIVATE LIMITED (IN) | 2016-09-15 | — | — | WO | disclosed |
| EP-2563847-B1 | MCR DENDRIMERS | LEIBNIZ INST FÜR PFLANZENBIOCHEMIE IPB (DE) | 2016-04-13 | — | — | EP | disclosed |
| US-9035070-B2 | Process for the preparation of 1-aryl-pyrazol-3-one intermediates useful in the synthesis of sigma receptors inhibitors | Esteve Química, S.A. (ES) | 2015-05-19 | — | — | US | disclosed |
| WO-2001074815-A2 | PHENYL-SUBSTITUTED IMIDAZOPYRIDINES | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2001-10-11 | — | — | WO | disclosed |
| WO-2001074814-A1 | PHENYL-SUBSTITUTED INDOLIZINE DERIVATIVES AND THEIR USE AS HISTAMINE H3 LIGANDS | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2001-10-11 | — | — | WO | disclosed |
| WO-2001074813-A2 | METHOD FOR USING 2- OR 3-ARYL SUBSTITUTED IMIDAZO[1,2-a] PYRIDINES AS H3 ANTAGONISTS | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2001-10-11 | — | — | WO | disclosed |
| US-4189611-A | USED TO MAKE DIOXOLANES WHICH ENDCAP AND COPOLYMERIZE WITH POLYOXYMETHYLENE GLYCOL MAKING IT HEAT RESISTANT, PRINTING PLATES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1980-02-19 | — | — | US | disclosed |
| US-4150989-A | RELIEF IMAGES, LITHOGRAPHIC PLATES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1979-04-24 | — | — | US | disclosed |
| US-4111960-A | Substituted dioxolanes and photosensitive and degradable polymers useful in imaging | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1978-09-05 | — | — | US | disclosed |
| US-4108839-A | RELIEF IMAGING AND LITHOGRAPHY | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1978-08-22 | — | — | US | disclosed |
| US-4075175-A | ANIONIC POLYMERIZATION | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1978-02-21 | — | — | US | disclosed |
| US-3991033-A | CONTAINING O-NITROPHENYL GROUPS | E. I. DU PONT DE NEMOURS & COMPANY (US) | 1976-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160343956-A1 | ORGANIC SOLAR CELL AND METHOD FOR MANUFACTURING SAME | DSG1, VCL, SUN2 | MAPT 1251/4885KDM4E 1000/4885L3MBTL1 3597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.